JP2021525758A5 - - Google Patents
Info
- Publication number
- JP2021525758A5 JP2021525758A5 JP2020566898A JP2020566898A JP2021525758A5 JP 2021525758 A5 JP2021525758 A5 JP 2021525758A5 JP 2020566898 A JP2020566898 A JP 2020566898A JP 2020566898 A JP2020566898 A JP 2020566898A JP 2021525758 A5 JP2021525758 A5 JP 2021525758A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- bladder cancer
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679495P | 2018-06-01 | 2018-06-01 | |
| US62/679,495 | 2018-06-01 | ||
| US201962826347P | 2019-03-29 | 2019-03-29 | |
| US62/826,347 | 2019-03-29 | ||
| PCT/US2019/034933 WO2019232392A1 (en) | 2018-06-01 | 2019-05-31 | Methods for the treatment of bladder cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525758A JP2021525758A (ja) | 2021-09-27 |
| JP2021525758A5 true JP2021525758A5 (enExample) | 2022-06-03 |
| JP7335277B2 JP7335277B2 (ja) | 2023-08-29 |
Family
ID=67138025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566898A Active JP7335277B2 (ja) | 2018-06-01 | 2019-05-31 | 膀胱がんの治療のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12251394B2 (enExample) |
| EP (1) | EP3801561B1 (enExample) |
| JP (1) | JP7335277B2 (enExample) |
| KR (1) | KR102993248B1 (enExample) |
| CN (1) | CN112512531B (enExample) |
| AU (1) | AU2019277679B2 (enExample) |
| BR (1) | BR112020024605A2 (enExample) |
| CA (1) | CA3101623A1 (enExample) |
| MX (1) | MX2020012964A (enExample) |
| SG (1) | SG11202011434SA (enExample) |
| WO (1) | WO2019232392A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| EP4398901A1 (en) | 2021-09-09 | 2024-07-17 | Eisai R&D Management Co., Ltd. | Biomarkers for sting agonists and methods of using the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
| CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP3233089A4 (en) | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| EP3676277A1 (en) | 2017-08-31 | 2020-07-08 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| US10947263B2 (en) | 2017-08-31 | 2021-03-16 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7208225B2 (ja) | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
-
2019
- 2019-05-31 US US17/058,817 patent/US12251394B2/en active Active
- 2019-05-31 CN CN201980050644.2A patent/CN112512531B/zh active Active
- 2019-05-31 SG SG11202011434SA patent/SG11202011434SA/en unknown
- 2019-05-31 EP EP19734956.6A patent/EP3801561B1/en active Active
- 2019-05-31 BR BR112020024605-0A patent/BR112020024605A2/pt active Search and Examination
- 2019-05-31 MX MX2020012964A patent/MX2020012964A/es unknown
- 2019-05-31 JP JP2020566898A patent/JP7335277B2/ja active Active
- 2019-05-31 CA CA3101623A patent/CA3101623A1/en active Pending
- 2019-05-31 WO PCT/US2019/034933 patent/WO2019232392A1/en not_active Ceased
- 2019-05-31 KR KR1020207037794A patent/KR102993248B1/ko active Active
- 2019-05-31 AU AU2019277679A patent/AU2019277679B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133474A5 (enExample) | ||
| JP2021098728A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP2023512175A5 (enExample) | ||
| JP2020033360A5 (enExample) | ||
| JP2024133475A5 (enExample) | ||
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| JP2016517434A5 (enExample) | ||
| MX2019012884A (es) | Terapia de combinacion. | |
| JP2016508134A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2014515373A5 (enExample) | ||
| JP2010527981A5 (enExample) | ||
| JP2018526460A5 (enExample) | ||
| JP2019515909A5 (enExample) | ||
| JP2022551691A5 (enExample) | ||
| Lasemi et al. | Articaine (4%) with epinephrine (1: 100,000 or 1: 200,000) in inferior alveolar nerve block: Effects on the vital signs and onset, and duration of anesthesia | |
| JP2015516419A5 (enExample) | ||
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| JP2024516359A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja |